ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Natural Bladder Control, Go Less and Live More

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Top Vitamin and Mineral Deficiencies — Are You at Risk?

How Pomegranate May Protect Against Cancer

Omega Fix for Obesity: How the Right Fats Fight Fat

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Fighting Heartburn and Gerd Naturally – And Safely!

Probiotics improve cognition in Alzheimer's patients

 
Print Page
Email Article

NIMH Genetics Initiative Study Steers Alzheimer's Disease Research in New Direction

  [ 7 votes ]   [ Discuss This Article ]
By Press Release by the National Institute of Mental • www.ProHealth.com • April 24, 1997


NIMH investigators have found in a sample of Alzheimer's disease (AD)-prone families that the Apolipoprotein E-4 (apoE-4) gene may exert its most marked effect in those in whom the disease develops at age 70 or younger. However, in this largest genetic study of AD to date, the gene remained a significant risk factor even at later ages.

The apoE-4 gene confers increased risk of developing AD, suggesting that it plays a significant role in the disease process. One copy of apoE-4 moderately increases an individual's risk of developing AD, while two copies confer a higher risk. At least one copy of the apoE-4 gene is borne by about one-half of those with AD in general population-based surveys, and by only about one-quarter of those without the disease.

The findings from the new report reaffirm the importance of this gene in conferring risk for AD and suggest that it asserts its maximal effect before age 70, at least in the families studied in this project. Combined results of large population-based studies will be necessary to determine the overall age-related risk conferred by the apoE-4 gene.

This study is the latest to suggest that additional genetic factors likely play a role in later onset forms of the disease. Steven E. Hyman, M.D., Director of the National Institute of Mental Health, whose Genetics Initiative funded the study, said, "These results should steer scientists to look for additional genetic clues to the later onset, more common form of this terrible, mind-destroying disease."

The newly published research is remarkable for its sample size of 679 individuals in 310 families, which was large enough for the researchers to separate out individuals by age at onset of AD symptoms. Rudolph E. Tanzi, Ph.D., of Harvard's Massachusetts General Hospital, the senior author of the study, said, "It remains critical to search for additional genes involved in the development of late-onset AD."

The newly published research also shows that in the studied families, several individuals over 80, who were Alzheimer's-free, carried two copies of the apoE-4 gene. So, said Dr. Tanzi, it seems premature to offer apoE testing as the sole predictive test for AD. This position is consistent with that of two national panels that examined the practical considerations regarding genetic assessment for AD using apoE-4. However, said Dr. Tanzi, genetic research carries the greatest promise to ultimately clarify mechanisms leading to the development of AD. "In the future, reliable genetic tests for AD could be used to identify those who are most likely to develop the disease," he said. "In this complex disease, such genetic tests might have to take into consideration the combined effects of multiple risk factor' genes and, perhaps, other non-genetic risk factors."

Dr. Tanzi's Harvard collaborators on the study, published in the January issue of Neurology, were lead authors, Deborah Blacker, M.D., Sc.D., and Jonathan Haines, Ph.D., along with principal investigator Marilyn S. Albert, Ph.D.


Source: National Institute of Mental Health
Press Release
April 24, 1997



Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Vitamin D3 Extreme™ FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map